Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above

Disease Types: Lymphoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above

For more information:

https://clinicaltrials.gov/ct2/show/NCT01716806?term=NCT01716806&draw=2&rank=1